Abstract Details
Activity Number:
|
217
|
Type:
|
Topic Contributed
|
Date/Time:
|
Monday, August 4, 2014 : 2:00 PM to 3:50 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #311462
|
View Presentation
|
Title:
|
Ensuring Data Quality and Identifying Potential Fraud in Clinical Trials
|
Author(s):
|
Nancy Geller*+
|
Companies:
|
NIH
|
Keywords:
|
fraudulent data ;
research misconduct ;
data integrity ;
detecting fraud
|
Abstract:
|
Research misconduct has been formally defined. After reviewing this definition, we are concerned with two aspects of research misconduct, falsification and/or fabrication of data which we loosely call "fraud". Several examples of fraud or allegation of fraud will be given in which we examine why fraud was alleged, how it has been detected and how long it took. Inquiries into publication fraud have been set off by an allegation (e.g. graduate students alleging data disappearance) or a strange and unexpected coincidence (e.g., consent forms missing). Statisticians are in a unique position to aid in the detection of fraud, but should play a more active role than attempting to detect fraud after the fact. One should be especially wary of results that appear to be "too good to be true." It is wise to undertake certain routine simple comparisons in all of our clinical trials to be assured that data or individual centers don't show unusual patterns. Making clinical trial data and computer code available to others promptly will allow verification of reported results.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2014 program
|
2014 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Professional Development program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.